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Animal ethicsAbstract The number of animals used in research has increased with the advancement of research
and development in medical technology. Every year, millions of experimental animals are used all
over the world. The pain, distress and death experienced by the animals during scientiﬁc experi-
ments have been a debating issue for a long time. Besides the major concern of ethics, there are
few more disadvantages of animal experimentation like requirement of skilled manpower, time con-
suming protocols and high cost. Various alternatives to animal testing were proposed to overcome
the drawbacks associated with animal experiments and avoid the unethical procedures. A strategy
of 3 Rs (i.e. reduction, reﬁnement and replacement) is being applied for laboratory use of animals.
Different methods and alternative organisms are applied to implement this strategy. These methods
provide an alternative means for the drug and chemical testing, up to some levels. A brief account of
these alternatives and advantages associated is discussed in this review with examples. An integrated
application of these approaches would give an insight into minimum use of animals in scientiﬁc
experiments.
ª 2013 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.Contents
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Use of animals for various purposes like food, transportation,
pets, sports, recreation and companionship is as old as the hu-
man beings itself. Using animals for the purpose of research is
one of the extended uses. Various animals like mice, rats, ham-
sters, rabbits, ﬁshes (examples – zebra ﬁsh, trout), birds
(mainly chicken), guinea pigs, amphibians (xenopus frogs),
primates, dogs, cats etc. are being used in research for a long
time (CULABBR, 1988). Drug testing and toxicological
screenings which are useful in the development of new treat-
ments for infectious and non-infectious diseases is the main
purpose of such studies. Animals also serve as a tool to under-
stand effects of medical procedures and surgical experiments.
Moreover, they are used to obtain products like vaccines, anti-
biotics etc. which are used in diagnostics as well as treatments
(Giacomotto and Segalat, 2010; Hendriksen, 2009, 2007). The
number of animals used in research has gone up with the
advancement in medical technology. Every year, millions of
experimental animals are used all over the world. For example,
in UK, 3.71 million animals were used for research in the year
2011 (www.rspca.org.uk). The total number of animals used in
the USA in the year 2009 was estimated to be 1,131,076, while
that in Germany reached up to 2.13 million in 2001 (Rusche,
2003). This huge population of experimental animals usually
comes from the breeding centers located in various universities
and national breeding centers. All of these are known as class-
A dealers, while the brokers who acquire the animals from mis-
cellaneous sources (like auctions and animal shelters) are iden-
tiﬁed as class-B dealers. At few instances use of the wild
animals such as monkeys and birds is also followed (Baumans,
2005). In clinical testing laboratories, animals are isolated from
their groups and used as a tool irrespective of their natural in-
stincts. For the experimental procedures, either a whole animal
or its organs and tissues are used. For this purpose animals are
euthanized (killed) by established methods. Many times, the
animals surviving the clinical testing are euthanized at the
end of an experiment to avoid the later pain and distress
(Rusche, 2003). In some cases (for example in LD 50 analysis)
animals die as a result of the experiment.
The pain, distress and death experienced by the animals
during scientiﬁc experiments have been a debating issue for a
long time. Argument is that being alive, animals have the
rights against pain and distress and hence, their use for exper-
imentation is unethical and must be stopped (Rollin, 2003).
Various acts and laws have been passed to bring the control
over unethical use of animals and minimize the pain to animals
during experimentation. For example, in 1824, the organiza-tion for animal rights was formed by the Royal Society for
the Prevention of Cruelty to Animals. In 1876, an act for pre-
vention of cruelty to animal was formed in the UK (Balls,
1994). It came into existence in India, France and USA in
the year 1960, 1963 and 1966, respectively. At present, many
rules and acts are followed at the international level, to protect
the animals against the cruelty and misuse. The organizations
like ICH (International Conference on Harmonization of tech-
nical requirements for registration of pharmaceuticals for hu-
man use), CPCSEA (Committee for Purpose of Control and
Supervision on Experiments on Animal), NIH (National Insti-
tute of Health), and OECD (Organization for Economic Co-
operation and Development) provide the guidelines for animal
house keeping, breeding, feeding, transportation, and mainly
for their use in scientiﬁc experiments (Rollin, 2003). Besides
the major concern of ethics, few more disadvantages of animal
experimentation are requirement of skilled/trained manpower
and time consuming protocols. Moreover, very high cost in-
volved in breeding, housing and lengthy protocols of animal
experiments is another drawback (Balls, 1994).
2. Three Rs: reduction, reﬁnement and replacement
Alternatives to animal testing were proposed to overcome
some of the drawbacks associated with animal experiments
and avoid the unethical procedures. A strategy of 3 Rs is being
applied which stands for reduction, reﬁnement and replace-
ment of laboratory use of animals (Ranganatha and Kuppast,
2012). Different methods and alternative organisms are ap-
plied to implement this strategy. The concept of replacement
of animals was ﬁrst discussed in 1957 by Charles Hume and
William Russell at the Universities Federation for animal wel-
fares (UFAW) (Balls, 1994). Russell and Burch (1959) sug-
gested some ways to make the animal experiments more
humanly, which was later called as 3 Rs. This approach moti-
vates the use of minimum number of animals i.e. ‘reduction’ in
the total number of animals used in an experiment. The use of
animals must be planned and ‘reﬁned’ carefully in such a way
that pain and distress caused during the experiment should be
minimized. Moreover, if possible higher animals should be ‘re-
placed’ with alternative methodologies and lower organisms
(Ranganatha and Kuppast, 2012; Zurlo et al., 1996). Animal
replacement is deﬁned as, ‘any scientiﬁc method employing
non-sentient material which may replace use of conscious liv-
ing vertebrates in animal experimentation’. Two types of
replacements were distinguished as ‘relative’ and ‘absolute’
replacement. In relative replacement the animals are used but
not exposed to any distress during experiment. No use of
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replacement strategy (Balls, 1994).
2.1. Reduction
With the help of statistical support and careful selection of
study design one can produce meaningful scientiﬁc results of
an experiment. For example, in vitro cell culture is a good
way to screen the compounds at early stages. Use of the human
hepatocyte culture gives the information about how a drug
would be metabolized and eliminated from the body. Inclusion
of such method in study design helps to eliminate unsuitable
compounds in preliminary stages only and minimizes the use
of animals in further tastings (Kimber et al., 2001). Live ani-
mals and embryos are used to study effects of some com-
pounds on embryo development. In vitro embryonic stem cell
culture test helps to reduce the number of live embryo used
and the compounds which are toxic toward developing embryo
(Gipson and Sugrue, 1994; De Silva et al., 1996). Also, sharing
or providing the discovered data (like characteristics of excip-
ients for the test drug) avoids the necessity of animal studies.
2.2. Reﬁnement
Enriching the cage environment by taking care of animals
reduces the stress on animals. Scientists should reﬁne the ani-
mal facility so that pain, discomfort and distress during animal
life and scientiﬁc procedures are reduced. Moreover, under the
stress and discomfort there may be imbalance in hormonal
levels of animals leading to ﬂuctuations in the results. Hence,
experiments need to be repeated which causes an increase in
the number of experimental animals. So reﬁnement is neces-
sary not only to improve the life of laboratory animals but also
to improve the quality of research (Hendriksen, 2009). For
example, it was observed that when mice genetically modiﬁed
to study Huntington’s disease were provided with a complex
cage environment with opportunity to nest, hide, gnaw and
forage, the disease progressed slowly than the mice in barren
cage. Also, such mice were found to mimic the progress of
the human disease more closely. Such a reﬁnement provides
a very good model to treat the disease and also minimize stress
to the animals (De Silva et al., 1996).
2.3. Replacement
Various alternatives to the use of animals have been suggested,
such as in vitro models, cell cultures, computer models, and
new imaging/analyzing techniques (Balls, 2002). The in vitro
models provide the opportunity to study the cellular response
in a closed system, where the experimental conditions are
maintained. Such models provide preliminary information
for outcome of an experiment in vivo. For example, computer
models were used to study the working of the heart and to
select the potential drug candidates (Gipson and Sugrue,
1994). In many countries, in vitro cell cultures have replaced
the skin irritancy test and Draize eye irritancy test and use
of animals in those. Another example is, extraction of insulin
from the pancreas of pigs and cow, but now it is obtained from
the bacterial cultures which are lifeline drugs for diabetic
patients. This extracted insulin needs to be checked for its
purity, efﬁcacy and dose. Use of animals was routine for suchchecking, but now chromatography techniques are used for
checking the purity, efﬁcacy and calculation of dosages of
drugs (Foreman et al., 1996). Overall, replacement substan-
tially reduces the use of animals in various processes.
3. Alternative methods
Various methods have been suggested to avoid the animal use
in experimentation. These methods provide an alternative
means for the drug and chemical testing, up to some levels.
Advantages associated with these methods are, time efﬁciency,
requires less man power, and cost effectiveness. These methods
are described in detail as follows-
3.1. Computer models
Computers can help to understand the various basic principles
of biology. Specialized computermodels and software programs
help to design new medicines. Computer generated simulations
are used to predict the various possible biological and toxic
effects of a chemical or potential drug candidate without animal
dissection. Only the most promising molecules obtained from
primary screening are used for in vivo experimentation. For
example, to know the receptor binding site of a drug, in vivo
experimentation is necessary. Software known as Computer
Aided Drug Design (CADD) is used to predict the receptor
binding site for a potential drugmolecule. CADDworks to iden-
tify probable binding site and hence avoids testing of unwanted
chemicals having no biological activity. Also, with the help of
such software programs we can tailor make a new drug for the
speciﬁc binding site and then in ﬁnal stage animal testing is done
to obtain conﬁrmatory results (Vedani, 1991). Hence, the total
number of experimental animals is lowered and the objectives
of Russel and Burche’s 3 Rs are achieved.
Another popular tool is the Structure Activity Relationship
(SARs) computer programs. It predicts biological activity of a
drug candidate based on the presence of chemical moieties at-
tached to the parent compound. Quantitative Structure Activ-
ity Relationship (QSAR) is the mathematical description of the
relationship between physicochemical properties of a drug
molecule and its biological activity (Knight et al., 2006). The
activities like carcinogenicity and mutagenicity of a potential
drug candidate are well predicted by the computer database.
The recent QSAR software shows more appropriate results
while predicting the carcinogenicity of any molecule. The
advantages of computer models over conventional animal
models are the speed and relatively inexpensive procedures
(Matthews and Contrera, 1998). A very good example is a
study by Dewhurst et al. (1994) which assessed the effective-
ness of computer models versus the traditional laboratory
practices. In this comparative study, two groups of undergrad-
uate students performed an experiment with the traditional wet
lab approach and computer assisted learning (CAL), respec-
tively. CAL is an interactive computer assisted learning
(CAL) program without involvement of real experimental
tools. At the end of the study both the groups were assessed
for the knowledge gain (through test questionnaires, calcula-
tions, and interpretation). It was found that the students
performing CAL had a better problem solving attitude.
Moreover, the cost of new techniques was much less than
the traditional laboratory practices (Dewhurst et al., 1994).
Table 1 Selected examples of organisms as alternatives for laboratory use of animals.
Alternative organism Remarks
Prokaryotes
Escherichia coli Model for molecular and genetic studies
Bacillus subtilis Model for cellular diﬀerentiation
Caulobacter crescentus
Protists
Dictyostelium discoideum Model for molecular and genetic studies
Fungi
Neurospora crassa Model for genetic study, circardian rhythm and metabolic regulation studies
Saccharomyces cerevisiae





Amphimedon queenslandica Studies on evolution, developmental biology and comparative genomics
Aplysia sp./sea slug Neurobiology
Caenorhabditis elegans Genetic development studies
Drosophila melanogaster Genetics and neurology research
Hydra/Cnidaria To understand the process of regeneration and morphogenesis
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Use of in vitro cell and tissue cultures which involves growth of
cells outside the body in laboratory environment can be an
important alternative for animal experiments. The cells and tis-
sues from the liver, kidney, brain, skin etc. are removed from
an animal and can be kept outside the body, in suitable growth
medium, for few days to several months or even for few years.
In vitro culture of animal/human cells includes their isolation
from each other and growing as a monolayer over the surface
of culture plates/ﬂasks. Cellular components like membrane
fragments, cellular enzymes can also be used. Various types
of cultures like cell culture, callus culture, tissue culture and or-
gan culture are used for various purposes. Beneﬁts associated
with techniques are, easy to follow, less time consuming and
are less expensive. These methodologies are routinely used
for preliminary screening of potential drug molecules/chemi-
cals to check their toxicity and efﬁcacy (Shay and Wright,
2000; Steinhoff et al., 2000). Almost all cosmetics, drugs and
chemicals are tested for their toxicity and efﬁcacy, using these
tests. For example, eye irritancy test. To check the irritancy of
chemicals previously Draize test was used, which requires ani-
mals (mainly rabbit). It is very painful and every time a new
animal is used. Ke Ping Xu and coworkers suggested an alter-
native which uses bovine corneal organ culture. The bovine
cornea is cultured up to three weeks in laboratory and various
analytical methods are used to evaluate the toxicological effect
of test chemical irritancy in vitro (Xu et al., 2000).
3.3. Alternative organisms
The ethical issues have posed many restrictions over the exper-
imental use of higher model vertebrates like guinea pig, rats,
dogs, monkeys etc. Therefore, use of alternative organisms
has been proposed. Different model organisms are used to re-
place experimental animals (Table 1).3.3.1. Lower vertebrates
Lower vertebrates are an attractive option because of the
genetic relatedness to the higher vertebrates including mam-
mals. Moreover, there are less ethical problems involved in
the experimental use of lower vertebrates.
3.3.1.1. Example – Danio rerio. Danio rerio, commonly called
as zebra ﬁsh, is a small freshwater ﬁsh with an approximate
length of 2–4 cm. It has a nearly transparent body during early
development, which helps easy visual access to the internal
anatomy. The optical clarity allows direct observation of
developmental stages, identiﬁcation of phenotypic traits dur-
ing mutagenesis, easy screening, assessment of endpoint of tox-
icity testing and direct observation of gene expression through
light microscopy. Small size, short life cycle and high fecundity
favor its laboratory use.
The working space, cost of laboratory solutions, test chem-
icals and the manpower involved are reduced by opting D. re-
rio as an alternative to animals (Hill et al., 2005). Its embryos
and larvae can be developed and used for testing in cell culture
plates and Petri dishes. Whole genome sequence availability
makes Zebra ﬁsh an attractive option for molecular and genet-
ic research. From infancy to the adult stage it is used in a vari-
ety of applications, mainly for the detection of various
toxicological studies of chemicals and pharmaceuticals. It is
also having wide applications in the investigation of cancer,
heart diseases, neurological malfunctions, behavioral diseases
and to observe the mutations and problems in organ develop-
ment due to exposure to test molecules. Modeling of certain
human diseases in zebra ﬁsh could be used to ameliorate the
disease phenotype and malfunctions in organ development
(Peterson et al., 2008).3.3.2. Invertebrates
Invertebrate organisms are widely used as an alternative for
laboratory use of animals. They have been used to study
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ory dysfunction, muscle dystrophy, wound healing, cell aging,
programmed cell death, retrovirus biology, diabetes and toxi-
cological testing (Lagadic and Caquet, 1998). Invertebrates
have an undeveloped organ system and do not have the adap-
tive immune system, which poses some limitations for their use
in human diseases. However, they hold numerous beneﬁts,
such as a brief life cycle, small size and simple anatomy, so that
a large number of invertebrates can be studied in a single
experiment within a short period with less ethical problems.
Their cost of housing is less compared to the animals. For
example, thousands of ﬂies could be accommodated in a shel-
ter where only few mice can be kept (Wilson-Sanders, 2011).
3.3.2.1. Example – Drosophila melanogaster. Drosophila mela-
nogaster, also known as fruit ﬂy is one of the most widely stud-
ied invertebrates in research (Gilbert, 2008). It has a well
studied genome which enables study of molecular mechanisms
underlying the human diseases. Its complete genome has been
sequenced and annotated, which encodes more than 14,000
genes on four chromosomes. Only three genes carry the bulk
of genome of D. melanogaster. Nearly 75% of the genes in-
volved in human diseases are believed to have a functional
homolog in the ﬂy (Reiter et al., 2001; Wilson-Sanders,
2011). D. melanogaster requires extremely low cost of mainte-
nance, propagation and screening as compared to the other
mammal based models. It also produces the results very rap-
idly due to a short life cycle. Fruit ﬂy possesses four stages
in life cycle – the embryo, the larva, the pupa and the adult.
Each stage of ﬂy has its own advantage, hence considered as
a multiple model organism to study the various concepts (Pan-
dey and Nichols, 2011). The Embryo is frequently used to
study the cell fate determination, neuronal development, axon
path ﬁnding, organogenesis, fundamental developments and to
examine pattern formation. The larva is used to study the
physiological and developmental processes and behaviors like
foraging. The adult ﬂy is a very complex organism. The func-
tions of various structures like the heart, lungs, gut, kidney and
reproductive tract are equivalent as that of mammals (Rothen-
ﬂuh and Heberlein, 2002).
The response of ﬂies to many drugs which are acting on
CNS is similar to that observed in mammals. The brain of
the adult ﬂy is quite extraordinary because more than
100,000 neurons form the discreet circuits, which mediate var-
ious complex behaviors like circadian rhythms, learning and
memory, feeding, sleep, courtship, aggression, grooming and
ﬂight navigation (Pandey and Nichols, 2011; Rothenﬂuh and
Heberlein, 2002; Wolf and Rockman, 2008). Number of
molecular and genetic tools has been made available to study
Drosophila. Due to many similarities in development and
behavioral activities, fruit ﬂy served as a unique and sensitive
model for the study of human genetics and diseases (Becking-
ham et al., 2005). It is also used to express the protein products
found in human diseases and to compare the resulting patho-
logic conditions. Fruit ﬂy serves as an important tool to inves-
tigate neurodegenerative diseases like Alzheimers, Parkinson’s,
disease and Huntington’s disease (Bonini and Fortini, 2003;
Iijima and Iijima-Ando, 2008; Iijima et al., 2004). It is used
in primary small molecule discovery validation as well as in
the target discovery processes by taking advantage of the
sophisticated genetics available in it. In 1994 the Nobel Prize
for physiology and medicine was awarded to Ed Lewis forhis pioneering research deﬁning gene structure in ﬂies, as well
as to Eric Weischaus and Christiane Nusslein-Volhard for
their studies investigating embryogenesis (Iijima et al., 2004).
3.3.2.2. Example – Caenorhabditis elegans. Caenorhabditis ele-
gans is a eukaryotic nematode. This multi cellular organism is
approximately 1 mm in length and has a very short generation
time. Complete life cycle of this hermaphrodite is about 2–
3 weeks. Embryogenesis occurs in 12 h and an adult form is
developed in 2.5 days. It is transparent, genetically amenable
and has simple cellular complexity. Hence, was selected as a
model organism by Nobel laureate Brenner (Barr, 2003;
Strange, 2007). Life cycle of C. elegans proceeds through var-
ious complex developmental stages like embryogenesis, mor-
phogenesis and growth to an adult. This is one of the most
commonly used model organisms for research purposes. Infor-
mation obtained can be applicable to more complex organisms
like humans. As a model, C. elegans have been used to study
various neurological disorders like Huntington’s disease, Par-
kinson’s disease, Alzheimer’s diseases; various immune disor-
ders as well as cancer, diabetes. It has served development
and testing of the therapeutic agents for treatment of these dis-
eases (Artal-Sanz et al., 2006; Faber et al., 1999; Link et al.,
2001; Nass et al., 2008; Pujol et al., 2008).
3.3.3. Microorganisms
3.3.3.1. Example – Saccharomyces cerevisiae. Brewing yeast,
Saccharomyces cerevisiae is the most popular and important
model organism due to its rapid growth, ease of replica plating
and mutant isolation, dispersed cells, well deﬁned genetic sys-
tem and highly versatile DNA transformation system. Yeasts
can be grown in solid or liquid culture and isolated as colonies
derived from a single cell on solid media. The generation time
is very short i.e. about 90 min, hence it is very easy to grow a
large population and analyze it (Mell and Burgess, 2002).
Whole genome of this unicellular fungus has been sequenced
in 1996. The nuclear genome contains about 16 chromosomes
with more than 13 million base pairs. It also contains an extra
nuclear genome in the mitochondria. The budding yeast carries
its genetic information in the form of 6000 genes. The number
and size of genes are relatively small and the density of genes is
very high. Best characterized and studied genome makes S.
cerveisiae one of the most ideal eukaryotic microorganisms
for the biological studies. Presence of similar cellular architec-
ture and rudimentary life cycle like multi cellular eukaryotes is
another advantage. The numerous membrane-bound organ-
elles like nucleus, peroxisome, mitochondria and the organelles
of secretary pathway also mimic the functions of mammalian
cells (Mell and Burgess, 2002). This brewing yeast is used to
understand programmed cell death, cell death regulators in hu-
mans and is very useful in cancer research (Madeo et al., 2002).
S. cerevisiae helps to understand the fundamental aspects of
cellular biology in neurodegenerative diseases like Alzheimer’s,
Parkinson’s and Huntington’s diseases by studying the endog-
enous or heterologous proteins that lay at the root of these dis-
eases (Pereira et al., 2012; Siggers and Lesser, 2008).4. Conclusion
Animal ethics is an issue as important as the human welfare.
More efforts need to be undertaken for effective implementation
228 S.K. Doke, S.C. Dhawaleof 3 Rs during laboratory use of animals. Various alternatives to
animal use have been suggested, which need to be implemented
in an effective manner. For this integration of various computer
models, bioinformatics tools, in vitro cell cultures, enzymatic
screens andmodel organisms are necessary. Use of modern ana-
lytical techniques, data acquisition and statistical procedures to
analyze the results of alternative protocols can provide depend-
able outcomes. These integrated approaches would result in
minimum involvement of animals in scientiﬁc procedures.Acknowledgements
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